Two Sigma Advisers’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2024
Q4 | – | Sell |
-185,058
| Closed | -$690K | – | 2594 |
|
2024
Q3 | $690K | Sell |
185,058
-39,759
| -18% | -$148K | ﹤0.01% | 1572 |
|
2024
Q2 | $1.26M | Sell |
224,817
-11,500
| -5% | -$64.4K | ﹤0.01% | 1431 |
|
2024
Q1 | $1.24M | Buy |
236,317
+14,300
| +6% | +$74.9K | ﹤0.01% | 1464 |
|
2023
Q4 | $1.16M | Buy |
222,017
+199,500
| +886% | +$1.04M | ﹤0.01% | 1568 |
|
2023
Q3 | $355K | Buy |
+22,517
| New | +$355K | ﹤0.01% | 1922 |
|
2021
Q4 | – | Sell |
-4,300
| Closed | -$240K | – | 2842 |
|
2021
Q3 | $240K | Sell |
4,300
-22,800
| -84% | -$1.27M | ﹤0.01% | 2189 |
|
2021
Q2 | $1.16M | Sell |
27,100
-84,600
| -76% | -$3.62M | ﹤0.01% | 1568 |
|
2021
Q1 | $4.66M | Buy |
111,700
+29,700
| +36% | +$1.24M | 0.01% | 878 |
|
2020
Q4 | $3.82M | Buy |
82,000
+66,900
| +443% | +$3.12M | 0.01% | 932 |
|
2020
Q3 | $641K | Buy |
15,100
+3,500
| +30% | +$149K | ﹤0.01% | 1710 |
|
2020
Q2 | $557K | Buy |
+11,600
| New | +$557K | ﹤0.01% | 1848 |
|
2019
Q3 | – | Sell |
-10,600
| Closed | -$590K | – | 2429 |
|
2019
Q2 | $590K | Buy |
10,600
+4,200
| +66% | +$234K | ﹤0.01% | 1743 |
|
2019
Q1 | $323K | Buy |
+6,400
| New | +$323K | ﹤0.01% | 1963 |
|
2018
Q3 | – | Sell |
-6,000
| Closed | -$454K | – | 2439 |
|
2018
Q2 | $454K | Buy |
+6,000
| New | +$454K | ﹤0.01% | 1956 |
|
2017
Q4 | – | Sell |
-4,800
| Closed | -$286K | – | 2407 |
|
2017
Q3 | $286K | Buy |
4,800
+1,500
| +45% | +$89.4K | ﹤0.01% | 1942 |
|
2017
Q2 | $260K | Buy |
+3,300
| New | +$260K | ﹤0.01% | 2040 |
|
2016
Q1 | – | Sell |
-36,491
| Closed | -$3.24M | – | 2158 |
|
2015
Q4 | $3.24M | Sell |
36,491
-23,709
| -39% | -$2.1M | 0.02% | 580 |
|
2015
Q3 | $4.47M | Buy |
60,200
+49,300
| +452% | +$3.66M | 0.03% | 500 |
|
2015
Q2 | $881K | Buy |
+10,900
| New | +$881K | 0.01% | 1178 |
|